D-I03 NEW
| Price | $31 | $70 | $128 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-15 |
Product Details
| Product Name: D-I03 | CAS No.: 688342-78-1 |
| Purity: 99.65% | Supply Ability: 10g |
| Release date: 2026/05/15 |
Product Introduction
Bioactivity
| Name | D-I03 |
| Description | D-I03 is a selective RAD52 inhibitor with a Kd of 25.8 μM. D-I03 inhibits RAD52-dependent single-strand annealing (SSA) and D-loop formation, with IC?? values of 5 μM and 8 μM, respectively. D-I03 exerts significant growth inhibition on BRCA1/2-deficient cancer cells but has no effect on RAD51. D-I03 can be used in combination therapy studies for tumors with DNA damage repair defects. |
| In vitro | Methods: In BRCA1-mutant UWB1.298 and MDA-MB-436 cells, medium containing different concentrations of D-I03 (0 μM, 2.5 μM, 5 μM, and 10 μM) was added on days 1 and 3, respectively. On day 4, cells were harvested and viable cells were counted using the trypan blue exclusion Methods. An equal number of viable cells were then subcultured into fresh 6-well plates and cultured in drug-free normal medium for approximately 2 weeks to allow single cells to proliferate and form colonies. Results: D-I03 significantly inhibited colony formation in a dose-dependent manner within the concentration range of 2.5–10 μM.[1] |
| In vivo | Methods: Using a BRCA2-deficient, PARP inhibitor-resistant ovarian cancer C57BL/6 mouse model, mice received olaparib (75 mg/kg, oral infusion), D-I03 (25 mg/kg, intraperitoneal injection), olaparib plus D-I03, or vehicle treatment for 20 days. Results: Combination therapy with D-I03 and PARP inhibitors reduced tumor burden and prolonged survival.[2] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 90 mg/mL (209.97 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 3.3 mg/mL (7.7 mM), Sonication is recommended. |
| Keywords | RNASynthesis | RNA Synthesis | RAD52 | DNASynthesis | DNA Synthesis | DI-03 | D-I03 | DI 03 |
| Inhibitors Related | 5-Fluorouracil | Adenine hemisulfate | Erythromycin thiocyanate | Guanidine hydrochloride | Hexane-1,6-diol | 1,4-Naphthoquinone | Adenine | Vidarabine | Carbazole | Thymidine | Docosanoic acid | Usnic Acid |
| Related Compound Libraries | DNA Damage & Repair Compound Library | Bioactive Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Cell Cycle Compound Library | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP3Y
|
Sichuan HongRi Pharma-Tech Co.,Ltd
|
2026-06-29 | ||
| $999.00 |
VIP2Y
|
HEBEI SHENGSUAN CHEMICAL INDUSTRY CO.,LTD
|
2026-06-28 | |
|
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-06-05 | ||
| $31.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-05-15 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY